Bonharen IV 60mg for treatment of joint disease associated with non-infectious synovitis. Bonharen gives systemic intravenous treatment. Joint disease affects not only the articular cartilage, but also the surrounding soft tissues and vascular system. The main protective anti-inflammatory effect of IVN administration of sodium hyaluronate is achieved through formation of the protective glycocalyx coating on the lumen of blood vessels. The glycocalyx prevents vascular leakage and reduces penetration of inflammatory me-diators into the surrounding tissue of the joint. The interaction of exogenous intravenously applied HA has been described as protection against inflammatory stimuli like LPS (bacterial endotoxin).

Treatment consists of one vial of 6ml per week for 5 weeks. Bonharen IVN legal category is VPO.For more info contact your Interchem territory manager.